Stock Groups

EU begins real-time review of AstraZeneca COVID-19 antibody cocktail By Reuters

[ad_1]

© Reuters. FILEPHOTO: AstraZeneca’s logo can be seen outside of its North America headquarters at Wilmington, Delaware (U.S.), March 22, 2021. REUTERS/Rachel Wisniewski

(Reuters] – AstraZeneca, the European Union’s medicines regulator, announced on Thursday that it had begun a real time review of its antibody-based COVID-19 Therapy. This was after the combination medicine proved to be effective in treating severe diseases.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, futures, indexes and Forex. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]